Archive · 8 Aug 2025
Mounjaro Leads Wegovy in India's Weight-Loss Injection Market
In India, two weight-loss injections are competing.
Mounjaro is currently winning because it was launched earlier, is slightly more effective, and has been promoted a lot.
In July 2025, Mounjaro made about 30 times more sales than Wegovy.
Mounjaro helps people lose more weight than Wegovy.
Some celebrities have also talked about using Mounjaro.
Although Mounjaro is leading, Wegovy could still become very popular later on.
Mounjaro dominates India's weight-loss injection market, with significantly higher sales than Wegovy.
In July 2025, Mounjaro sales reached Rs 47 crore compared to Wegovy's Rs 7 crore.
Mounjaro has a slight edge in weight loss efficacy, with patients losing more weight compared to Wegovy users.
Mounjaro's early launch, aggressive marketing, and celebrity endorsements have contributed to its lead.
Experts believe Wegovy has strong growth potential despite the initial gap in sales.
- Who
- Mounjaro (tirzepatide) and Wegovy (semaglutide)
- What
- Mounjaro leads Wegovy in the Indian weight-loss injection market.
- When
- Sales data is from July 2025.
- Where
- India
- Why
- Mounjaro's early launch and marketing contributed to its lead.
Mounjaro's Dominance
Wegovy's Potential
Efficacy vs. Growth Potential
Mounjaro's Dominance
Mounjaro has superior weight loss efficacy.
Wegovy's Potential
Wegovy's potential for market growth.
- Mounjaro July 2025 Sales
- Rs 47 crore
- Wegovy July 2025 Sales
- Rs 7 crore
- Mounjaro Launch
- March
- Wegovy Launch
- July
- Mounjaro average weight loss (meta-analysis)
- 11.4%
- Wegovy average weight loss (meta-analysis)
- 7.3%
- Mounjaro cost per month
- Rs 14,000 to Rs 17,500
- Wegovy cost per month
- Rs 17,000 to Rs 26,000